TMA-2

Discovery

Viktor Bruckner first synthesized 2,4,5-trimethoxyamphetamine in 1933 during chemical research unrelated to psychopharmacology.^[4] The compound attracted no further attention until Alexander Shulgin independently prepared it in 1962 and conducted systematic self-experimentation. His 1964 publication in Experientia constituted the first scientific report of TMA-2's psychoactive effects, describing them as mescaline-like but notably lacking in color enhancement and more prone to anxiety.^[5]

Publication and significance

Shulgin and Shulgin's PiHKAL: A Chemical Love Story (1991) provided detailed synthesis instructions and human dose-effect data for TMA-2 as Entry #158.^[4] This entry became the primary reference for the compound and remained the sole source of human pharmacological data for subsequent decades. TMA-2's principal scientific value lies as a structural reference point in phenethylamine structure-activity relationship studies — the methoxy-substituted anchor of the DOx series.

Prohibition and modern status

In 2003, the EMCDDA conducted a formal risk assessment finding no reports of toxic effects or deaths from TMA-2 in humans within the EU.^[7] Despite this finding, EU Council Decision 2003/847/JHA mandated control measures and criminal sanctions across all member states.^[8] Since scheduling, TMA-2 has appeared sporadically in forensic drug monitoring in Japan and Europe as a minor component of designer drug markets,^[9] and no clinical research programs have investigated it for any therapeutic indication.

Structural class

TMA-2 belongs to the DOx series — a family of 4-substituted 2,5-dimethoxyamphetamines within the broader substituted phenethylamine class.^[2] It shares the 2,5-dimethoxy-phenylisopropylamine backbone with DOM, DOI, and DOB, differing only at the 4-position: a methoxy group where DOM carries a methyl, DOI an iodine, and DOB a bromine.

Molecular properties

The core structure consists of a phenyl ring bearing three methoxy substituents at the 2, 4, and 5 positions, linked via a two-carbon chain to an alpha-methylamine group — the isopropylamine side chain characteristic of all amphetamines.^[10][11]

Stereochemistry

The alpha-carbon constitutes a stereocenter, yielding (R)- and (S)-enantiomers. TMA-2 is typically encountered as the racemic mixture.^[10] No enantiomer-specific pharmacological data have been published. In related compounds, the (R)-enantiomer typically shows greater 5-HT₂A affinity, but this remains unconfirmed for TMA-2.

Structure-activity relationships

The 2,5-dimethoxy motif is critical for psychedelic potency. Removing either the 2- or 5-methoxy group sharply reduces activity in animal models, even when receptor binding decreases only modestly.^[12] TMA-2's 4-methoxy substituent makes it the least potent DOx member — replacing the methoxy with a halogen (DOB, DOI) or a methyl group (DOM) increases potency substantially, reflecting the greater electron-withdrawing and lipophilic character of those substituents.

Physical properties

The hydrochloride salt melts at 188.5–189.5°C.^[11] No published solubility, partition coefficient, or stability data exist. Based on structural class, the hydrochloride salt is expected to be freely soluble in water.

Mechanism of action

TMA-2 produces its psychedelic effects primarily through activation of the serotonin 5-HT₂A receptor.^[2][13] Despite relatively weak binding affinity at this receptor, the compound achieves near-full functional activation — a pattern indicating that it needs to occupy only a small fraction of available receptors to produce its effects.^[2]

The 2,5-dimethoxy substitution pattern on the phenyl ring is essential for this activity. Removing either methoxy group from the ring dramatically reduces psychedelic potency in animal models, even when receptor binding changes only modestly.^[12]

Unlike stimulant amphetamines such as amphetamine or MDMA, TMA-2 exerts minimal influence on monoamine reuptake and release.^[3] Its psychoactive profile is driven almost entirely by serotonin receptor agonism rather than catecholamine activity. It is also essentially inactive at TAAR1.^[2]

Pharmacokinetics

No human pharmacokinetic studies have been published. All timing estimates — onset of 20–120 minutes and total duration of 8–12 hours — derive from Shulgin's self-experimentation.^[4] Peak plasma concentration, half-life, bioavailability, and distribution volume remain unknown in humans.

In rat models, TMA-2 is metabolized primarily through removal of methoxy groups (O-demethylation), with the 4-position methoxy group preferentially targeted.^[14] The resulting metabolites undergo further processing and are excreted as conjugated forms.

The liver enzyme CYP2D6 handles the primary metabolic step.^[15] TMA-2 weakly inhibits this enzyme — far less potently than established CYP2D6 inhibitors — a finding relevant to potential drug interactions but unlikely to be clinically significant at typical doses.^[15]

Where it acts

No direct neuroimaging or electrophysiology studies have been conducted with TMA-2. Its confirmed 5-HT₂A agonism^[2][13] places it within the same mechanistic framework as other serotonergic psychedelics: activation of 5-HT₂A receptors on deep-layer neurons in the prefrontal cortex, leading to increased excitatory signaling and disruption of the brain's default filtering circuits.

In mice, TMA-2 produces locomotor hyperactivity that is blocked by a selective 5-HT₂A antagonist,^[13] confirming this pathway drives its behavioral effects. The prominent stimulation and restlessness reported in humans likely reflects this cortical excitation.

Why it matters

The REBUS model proposes that 5-HT₂A agonists loosen the brain's reliance on learned predictions, allowing raw sensory information to flow more freely through cortical networks. TMA-2's reported effects — altered thought connectivity and conceptual thinking alongside relatively muted visuals — fit this framework but suggest the compound may engage visual processing circuits less strongly than mescaline.

Whether TMA-2 promotes structural changes in neurons (neuroplasticity) remains untested. Its close structural relative DOI is a well-characterized promoter of dendritic growth, making this plausible but unconfirmed.

Toxicity

No lethal dose data exist for TMA-2 in any species, and no animal toxicology studies have been published. The toxic dose in humans is unknown.safety citation needed

As of the 2003 EMCDDA risk assessment, no reports of toxic effects or deaths from TMA-2 had been documented in the EU.^[7] No case reports of serious adverse events, hospitalizations, or fatalities attributed to TMA-2 have appeared in published literature through 2026.

TMA-2's activity at serotonin₂B receptors is unknown. Some serotonin-active drugs (notably fenfluramine) damage heart valves through this receptor, and certain structurally related compounds (DragonFLY series) produce severe blood vessel constriction. Whether TMA-2 carries either risk is uncharacterized.

Psychological risks

TMA-2 carries elevated psychological risk relative to mescaline. Effects are highly variable between individuals and sessions, with greater propensity for anxiety, dysphoria, and restlessness.^[4] The 8–12 hour duration extends the window of vulnerability for acute psychological distress compared to shorter-acting psychedelics.

No systematic assessment of persisting perceptual changes (HPPD), psychosis precipitation, or psychiatric destabilization has been conducted for TMA-2. Class-level evidence from serotonergic psychedelics indicates these risks are rare but real, particularly in individuals with personal or family history of psychotic disorders.

Tolerance and dependence

Tolerance develops rapidly through 5-HT₂A downregulation.^[16][6] Studies with the close structural analog DOI show measurable tolerance within 24 hours of a single dose, with receptor density recovering over approximately 3 days and full functional reset at approximately 7 days.^[6][16]

Cross-tolerance with all classical serotonergic psychedelics — including LSD, psilocybin, mescaline, and other DOx compounds — is expected based on the shared 5-HT₂A mechanism.^[6]

TMA-2 is not habit-forming. No evidence of physical dependence, withdrawal, or compulsive use has been reported for TMA-2 or the DOx class.

Drug interactions

All interaction data for TMA-2 are class-level inferences. No substance-specific drug interaction studies have been published.

MAO inhibitors pose a theoretical serotonin syndrome risk. Although TMA-2's minimal monoamine transporter activity^[3] makes direct serotonin release amplification unlikely, its potent 5-HT₂A agonism could synergize with monoamine oxidase inhibition to produce serotonin toxicity.^[17]

SSRIs and SNRIs may weaken TMA-2's psychedelic effects through chronic 5-HT₂A downregulation, a class effect established for other serotonergic psychedelics.^[17] Acute serotonergic potentiation is also theoretically possible — the interaction is bidirectional and unpredictable.

CYP2D6 substrates may be affected by TMA-2's weak competitive inhibition of this enzyme.^[15] Clinically relevant interactions are unlikely at typical doses but cannot be excluded in CYP2D6 poor metabolizers or with narrow-therapeutic-index drugs (codeine, tramadol, tamoxifen, certain antidepressants).

Lithium combined with classical psychedelics is flagged as a risk for seizures and unpredictable potentiation at the class level. No TMA-2-specific data exist.citation needed

Contraindications

Psychotic disorders and family history of psychosis are absolute contraindications based on the established risk of psychosis precipitation by serotonergic psychedelics.inferred

Heart conditions, including high blood pressure, irregular heartbeat, and structural heart disease, are relative contraindications given TMA-2's reported vasoconstriction and cardiac effects across its prolonged 8–12 hour duration.

Concurrent MAOI use is contraindicated due to theoretical serotonin syndrome risk.^[17]

Pregnancy is an absolute contraindication — no reproductive safety data exist, and 5-HT₂A agonists are not established as safe during pregnancy.inferred

Seizure disorders are a relative contraindication, as phenethylamine psychedelics may lower seizure threshold through cortical excitation.inferred

TMA-2 is controlled in most major jurisdictions. Despite the 2003 EMCDDA finding of no documented toxic effects or fatalities,^[7] regulatory action proceeded on the basis of structural classification and predicted pharmacological activity. TMA-2 is not listed in the UN Convention on Psychotropic Substances (1971) schedules.

Scheduling ambiguity

TMA-2's US scheduling status is technically ambiguous. The compound is not individually named in the DEA Orange Book. Control is highly probable through positional isomer provisions under 3,4,5-trimethoxyamphetamine (Schedule I, DEA Code 7390) or through the Federal Analogue Act when intended for human consumption. Cayman Chemical, a US-regulated research chemical supplier, describes TMA-2 as "regulated as a Schedule I compound in the United States".^[11]